Genmab Partners With Incyte on Metastatic Colorectal Cancer Trial
Bitget2026/10/24 11:01- Genmab entered a clinical trial collaboration with Incyte and will conduct a Phase 1/2 study.
- The study will test petosemtamab with INCB161734 and chemotherapy as first-line treatment for KRAS G12D-mutated metastatic colorectal cancer.
- Incyte will co-fund the study and provide clinical supplies of INCB161734.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan maintains “Overweight” rating on Unilever (UL.US): The new mid-term framework strengthens growth quality, and high single-digit EPS growth is expected to drive revaluation.
JPMorgan released a research report, maintaining an "Overweight" rating for Unilever and setting its European stock target price at 65 euros and its UK stock target price at 5,700 pence.
Hemnet Appoints Michael Hansen as Interim CEO
Toyota Motor (TM.US) to announce earnings tomorrow: Analysts expect Q2 profit to increase by 18% year-on-year, marking the first growth in six quarters
Toyota Motor’s profit for the second quarter is expected to grow by 18%, marking the first increase in six quarters.
Crypto prices
More
